iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Zydus launches Lenalidomide Capsules in the US market

23 Sep 2022 , 01:33 AM

Zydus Lifesciences has launched Lenalidomide Capsules in the US The company had earlier received final approvals for 5 mg 10 mg 15 mg and 25 mg strengths and tentative approvals for 25 mg and 20 mg strength USRLD Revlimid Lenalidomide is used to treat various types of cancers It works by slowing or stopping the growth of cancer cells It is also used to treat anemia in patients with certain bloodbone marrow disorders myelodysplastic syndromes-MDS The drug is being manufactured at the groups formulation manufacturing facility at Ahmedabad SEZ India Lenalidomide had annual sales of USD 286 bn in the United States according to IQVIA MAT July 2022

Related Tags

  • Announcements
  • BSE
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.